tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate

Catalog No. :
ACRPCM820
CAS No. :
719310-31-3
Molecular Formula :
C13H16BrNO3
Molecular Weight :
314.18

IUPAC Name:tert-butyl 6-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate

tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$88.00Login to see priceIn stockInquiry
10g95%$153.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate
IUPAC Nametert-butyl 6-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate
MDL No.MFCD11865220
Molecular FormulaC13H16BrNO3
Molecular Weight314.18
SMILESO=C(N1C2=CC(Br)=CC=C2OCC1)OC(C)(C)C
InChI KeyJOFHRALTEXLLIC-UHFFFAOYSA-N
Synonym719310-31-3 | tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate | 4-BOC-6-Bromo-2,3-dihydro-1,4-benzoxazine | 6-Bromo-4-Boc-2,3-dihydro-benzo[1,4]oxazine | tert-butyl 6-broMo-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate | MFCD11865220 | tert-butyl 6-bromo
CAS No.719310-31-3
PubChem CID56776935

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACRPCM820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZLXB526 route compound structure diagram
    ACZLXB526105655-01-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRPCM820 route product structure diagram
    ACRPCM820719310-31-3 In Stock
Inquiry

2. ACRPCM820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRPCM820 route product structure diagram
    ACRPCM820719310-31-3 In Stock
Inquiry

Comments (0)